# Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers

> **NCT05730842** · PHASE1 · COMPLETED · sponsor: **Edgewise Therapeutics, Inc.** · enrollment: 15 (actual)

## Conditions studied

- Healthy Volunteer
- Muscular Dystrophies
- Muscular Disorders, Atrophic
- Muscular Diseases
- Musculoskeletal Diseases
- Neuromuscular Diseases
- Nervous System Diseases
- Genetic Diseases, Inborn

## Interventions

- **DRUG:** EDG-5506 Tablet
- **DRUG:** Radiolabeled EDG-5506 Suspension
- **DRUG:** Radiolabeled EDG-5506 Intravenous

## Key facts

- **NCT ID:** NCT05730842
- **Lead sponsor:** Edgewise Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-12
- **Primary completion:** 2023-04-06
- **Final completion:** 2023-04-06
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05730842

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05730842, "Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05730842. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*